18,236 Viking Therapeutics, Inc. $VKTX Shares Purchased by Fulcrum Asset Management LLP

Fulcrum Asset Management LLP grew its position in Viking Therapeutics, Inc. (NASDAQ:VKTX) by 118.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 33,569 shares of the biotechnology company’s stock after purchasing an additional 18,236 shares during the quarter. Fulcrum Asset Management LLP’s holdings in Viking Therapeutics were worth $1,068,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Cornerstone Capital Inc. purchased a new stake in shares of Viking Therapeutics in the 2nd quarter valued at $3,334,000. Timothy G. Youngquist 2020 Irrevocable Trust grew its holdings in Viking Therapeutics by 141.6% in the second quarter. Timothy G. Youngquist 2020 Irrevocable Trust now owns 271,849 shares of the biotechnology company’s stock valued at $10,605,000 after purchasing an additional 159,349 shares during the period. BlackRock Inc. purchased a new stake in shares of Viking Therapeutics in the second quarter valued at approximately $241,458,000. Dimensional Fund Advisors LP raised its stake in shares of Viking Therapeutics by 18.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 542,516 shares of the biotechnology company’s stock worth $17,653,000 after buying an additional 82,941 shares during the period. Finally, Bank of America Corp DE purchased a new position in Viking Therapeutics in the 2nd quarter valued at about $14,971,000. 76.03% of the stock is owned by hedge funds and other institutional investors.

Viking Therapeutics Stock Down 0.8%

Shares of NASDAQ VKTX opened at $28.44 on Thursday. The stock has a market cap of $3.63 billion, a P/E ratio of -5.27 and a beta of 0.79. The business’s fifty day simple moving average is $29.54 and its 200-day simple moving average is $32.20. Viking Therapeutics, Inc. has a 12-month low of $23.82 and a 12-month high of $43.15. The company has a current ratio of 7.27, a quick ratio of 7.27 and a debt-to-equity ratio of 0.43.

Viking Therapeutics (NASDAQ:VKTX) last released its earnings results on Wednesday, October 28th. The biotechnology company reported ($1.55) EPS for the quarter, missing the consensus estimate of ($1.06) by ($0.49). During the same period in the previous year, the business earned ($0.81) earnings per share. As a group, equities analysts predict that Viking Therapeutics, Inc. will post -5.26 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on VKTX shares. Zacks Research raised shares of Viking Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 18th. Truist Financial decreased their price target on Viking Therapeutics from $87.00 to $85.00 and set a “buy” rating on the stock in a research note on Wednesday, October 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Viking Therapeutics in a research report on Thursday, October 15th. Oppenheimer set a $120.00 target price on Viking Therapeutics in a research report on Tuesday, September 22nd. Finally, The Goldman Sachs Group reiterated a “neutral” rating and set a $34.00 price target on shares of Viking Therapeutics in a research note on Thursday, October 29th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Viking Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $93.36.

About Viking Therapeutics

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California. Founded in 2012, it develops medicines for metabolic and endocrine disorders and does not have commercially marketed products. The company’s pipeline includes VK2735, an investigational drug that targets the GLP-1 and GIP receptors and is being developed for obesity, and VK2809, a thyroid hormone receptor beta agonist being studied for metabolic and liver conditions. Viking is also developing VK0214 for X-linked adrenoleukodystrophy, a rare genetic disorder.